Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
Completed · Phase 4
Conditions studied: Crohn's Disease
In brief
The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.
Key facts
- Study ID
- NCT00280956
- Run by
- Biogen
- People needed
- 2000
- Starts
- 2002-07-01
- Expected to finish
- 2004-09-01
- Last updated by the study team
- 2016-06-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Performed only at CD251, CD301, CD303, CD306, and CD307 sites globally. No general public enrollment. The study is managed from the office of Elan Pharmaceuticals, Inc. in — San Diego, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.